AngioDynamics To Report Fiscal 2013 Fourth Quarter And Full Year Financial Results And Hold Conference Call On July 11, 2013

ALBANY, N.Y., June 25, 2013 (GLOBE NEWSWIRE) -- AngioDynamics (Nasdaq:ANGO), a leading provider of innovative, minimally invasive medical devices for vascular access, surgery, peripheral vascular disease and oncology, today announced it will report financial results for its fiscal 2013 fourth quarter and full year ended May 31, 2013, on Thursday, July 11, 2013, after the close of the U.S. financial markets.

Management will host a conference call beginning at 4:30 p.m. Eastern Daylight Time on July 11, 2013, to discuss the results and to answer questions.

To participate in the live call by telephone, please call 1-877-941-0844.

A live webcast and subsequent archived replay of the conference call may be accessed via the investor relations section of the Company's website under "Events & Presentations" at . To listen to the live webcast, please go to the website 15 minutes prior to its start to register, download and install the necessary audio software.

About AngioDynamics

AngioDynamics Inc. is a leading provider of innovative, minimally invasive medical devices used by professional healthcare providers for vascular access, surgery, peripheral vascular disease and oncology. AngioDynamics' diverse product lines include market-leading ablation systems, fluid management systems, vascular access products, angiographic products and accessories, angioplasty products, drainage products, thrombolytic products and venous products. More information is available at .


AngioDynamics and the AngioDynamics logo are trademarks and/or registered trademarks of AngioDynamics Inc., an affiliate or a subsidiary.
CONTACT: Company Contact:         AngioDynamics, Inc.         Mark Frost, CFO         (800) 772-6446 x1981                  Investor Relations Contacts:         EVC Group, Inc.         Michael Polyviou/Robert Jones         (212) 850-6020; (646) 201-5447;                  Media Contact:         EVC Group, Inc.         Chris Gale         (646) 201-5431

If you liked this article you might like

Endo international, AngioDynamics Lead Biotech Movers

As Economic Danger Looms, Will Entrepreneurs Come to the Rescue?

5 Stocks Everyone Hates -- but You Should Love

AngioDynamics (ANGO) Strong On High Relative Volume Today

5 Hated Earnings Stocks You Should Love